Sanofi: Form 20-F/A for the period ended Dec 31, 2017
Filed with the SEC on Mar 16, 2018 and accepted by EDGAR at Mar 16, 2018, 07:55 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | EUR 11.61bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | EUR 24.59bn | ifrs-full:GrossProfit |
| Operating income | 12 months2017-01-01 to 2017-12-31 | EUR 5.80bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2017-01-01 to 2017-12-31 | EUR 1.72bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2017-01-01 to 2017-12-31 | EUR 8.43bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | EUR 6.66 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | EUR 6.71 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | EUR 7.38bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2017-12-31 | EUR 10.31bn | ifrs-full:CashAndCashEquivalents |
| Total assets | At period end2017-12-31 | EUR 99.83bn | ifrs-full:Assets |
| Shareholders' equity | At period end2017-12-31 | EUR 58.09bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2017-12-31 | 1,254,019,904 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001193125-18-084834. Last ingested by Listed: Nov 5, 2026, 12:26 ET. Listed shows no prices and gives no investment advice.